Hikma Pharmaceuticals Plc Total Voting Rights
February 01 2024 - 7:08AM
RNS Regulatory News
RNS Number : 7402B
Hikma Pharmaceuticals Plc
01 February 2024
Hikma Pharmaceuticals
PLC
(the
Company)
Total Voting Rights and
Capital
LONDON, 1 February 2024 - In
accordance with section 5.6.1 of the UK Financial Conduct
Authority's Disclosure Guidance and
Transparency Rules (the 'Rules'),
Hikma Pharmaceuticals PLC
(LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies
the market of the following:
As at 31 January 2024,
the issued share capital of the Company
comprised of 221,081,676
Ordinary Shares of 10
pence each ('Shares') with voting rights. This figure excludes 12,833,233 Shares held in treasury, which
do not have voting rights.
The figure of 221,081,676 may be
used by shareholders (and others with notification obligations) as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company under the Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
|
|
Helen Middlemist
Group Company Secretary
|
+44 20
7399 2760
|
About Hikma
Hikma helps put better health within
reach every day for millions of people around the world. For more
than 45 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
North America, the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,800 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit:
www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVREAAAFEEPLEFA
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024